- Home
- ERAS vs PACB Comparison
ERAS vs PACB Comparison
Compare ERAS & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- PACB
- Stock Information
- Founded
- ERAS 2018
- PACB 2000
- Country
- ERAS United States
- PACB United States
- Employees
- ERAS N/A
- PACB N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- ERAS Health Care
- PACB Industrials
- Exchange
- ERAS Nasdaq
- PACB Nasdaq
- Market Cap
- ERAS 396.6M
- PACB 364.2M
- IPO Year
- ERAS 2021
- PACB 2010
- Fundamental
- Price
- ERAS $1.39
- PACB $1.12
- Analyst Decision
- ERAS Strong Buy
- PACB Buy
- Analyst Count
- ERAS 6
- PACB 10
- Target Price
- ERAS $4.83
- PACB $2.45
- AVG Volume (30 Days)
- ERAS 1.4M
- PACB 6.4M
- Earning Date
- ERAS 05-20-2025
- PACB 05-08-2025
- Dividend Yield
- ERAS N/A
- PACB N/A
- EPS Growth
- ERAS N/A
- PACB N/A
- EPS
- ERAS N/A
- PACB N/A
- Revenue
- ERAS N/A
- PACB $152,357,000.00
- Revenue This Year
- ERAS N/A
- PACB $6.13
- Revenue Next Year
- ERAS N/A
- PACB $21.55
- P/E Ratio
- ERAS N/A
- PACB N/A
- Revenue Growth
- ERAS N/A
- PACB N/A
- 52 Week Low
- ERAS $1.01
- PACB $1.06
- 52 Week High
- ERAS $3.45
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- ERAS 51.46
- PACB 44.27
- Support Level
- ERAS $1.37
- PACB $1.06
- Resistance Level
- ERAS $1.61
- PACB $1.23
- Average True Range (ATR)
- ERAS 0.14
- PACB 0.07
- MACD
- ERAS 0.00
- PACB 0.01
- Stochastic Oscillator
- ERAS 45.68
- PACB 31.58
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.